Release Therapeutics to present at the Emerging Biotech Company Track, Swiss Biotech Day 2025 (11 April 2025)
- Release Tx
- 3 hours ago
- 1 min read
We are thrilled to announce that Release Therapeutics has been selected to present at the Emerging Biotech Company Track at Swiss Biotech Day 2025, which will take place on 5-6 May at the Congress Center in Basel.
Our CEO, Julien Grogg, PhD, MBA, will take the stage on Tuesday, 6 May to present our latest advancements with the Myo-P4®, the first intracerebral enzyme replacement therapy for patients with metachromatic leukodystrophy (MLD). MLD is a rare, hereditary disorder of the CNS that tragically results in severe disability and early mortality in young children, often before they reach school age. The Myo-P4® stands to rewrite this story.
The Emerging Biotech Company Track features a curated group of companies, selected by invitation only by Pureos Bioventures and the Swiss Biotech Association, and we are honoured to be among them.
We look forward to connecting with fellow innovators, investors and partners in Basel.
The Release Tx Team